VP Medical Affairs & Chief Medical Officer (CMO)
Emmanuelle Dochy, MD, joined Transgene in September 2024 as Chief Medical Officer (CMO).
Emmanuelle Dochy was previously Vice President of Global Medical Affairs at Bayer, where she gained extensive experience in managing medical affairs on a global scale. With 15 years of experience in the pharmaceutical industry, she has held a variety of medical affairs, various strategic positions, focusing particularly on managing clinical trials from preclinical stages through advanced development.
Emmanuelle began her career at Sanofi Belgium, where she was responsible for Oncology. Among her notable achievements, she led the European launch of aflibercept for metastatic colorectal cancer and contributed to the development and submission of post-marketing approval files, particularly for new indications of docetaxel in the treatment of prostate cancer. Emmanuelle Dochy holds a medical degree from the Université Libre de Bruxelles and is specialized in Internal Medicine.
